In the field of innovative medicine, which pharmaceutical companies are favored?

[pharmaceutical network market analysis 】The Research Report on the market prospects and investment opportunities of China's pharmaceutical industry 2019-2024 issued by China business industry research institute points out that under the joint promotion of policies, capital, talents and other factors, pharmaceutical enterprises with outstanding R & D strength and strong ability to create new drugs will stand out, the R & D strategy and market strategy of pharmaceutical enterprises will usher in a great transformation, and innovative pharmaceutical enterprises will benefit from favorable policies So as to usher in good development opportunities In 2019, with the promotion of pharmaceutical policies such as volume purchase, the industry pattern is facing remodeling In the field of innovative drugs, the pharmaceutical industry is experiencing the process of transition from generic drugs to combination of generic drugs and innovative drugs On the whole, the competition in the field of innovative drugs in the future will be the pattern of the strong and the strong, and the innovation leader may get a good development space Some industry researchers say that the innovative drug companies that are optimistic about the market at present are those that carried out the layout of innovative drugs five years ago, such as China's Biopharmaceutics, etc The follow-up development will be that the enterprise will gradually maintain its core competitive advantage in the serious disease field through product iteration and channel pipeline depth, which requires investors to pay more attention to the company's R & D in a more forward-looking way The author understands that with innovation gradually becoming the core driving force to support the future development of enterprises, in recent years, domestic pharmaceutical enterprises continue to invest heavily in R & D, and the gap with international level gradually narrowed For example, Baiji Shenzhou invested 4.557 billion yuan in R & D in 2018, followed by Hengrui, which is 2.67 billion yuan It is estimated that R & D expenditure will exceed 3 billion yuan in 2019 Fosun and China biopharmaceutical followed closely, with R & D expenditure of 2.507 billion and 2.088 billion respectively in 2018 In the eyes of investors, there are many investment opportunities for innovative drug companies, but they can't do it Some data from the initial experiments have not come out yet, and the valuation has come up Therefore, investors are very concerned about the sustainable development of enterprises The dynamic adjustment of the 2019 version of the medical insurance catalog is conducive to the timely inclusion of innovative drugs into the medical insurance to achieve rapid volume Currently, promising innovative pharmaceutical enterprises in the industry include Hengrui pharmaceutical, Xinda biology, Kanghong pharmaceutical, Sansheng pharmaceutical, Lizhu group, etc Analysts in the pharmaceutical industry believe that with the environment of innovative drugs gradually improving, the future prospects of innovative drugs are also promising On the demand side, medical insurance policies and terminal payment capacity continue to improve Supply side policies and talents promote domestic innovative drugs to enter the golden harvest period The upstream and downstream levels of the industry are the same China's pharmaceutical innovation ushers in an opportunity period, and the industry will accelerate its rise   It can be seen that since 2019, with the frequent emergence of domestic innovative drug support policies, such as drug review and approval reform, tax preference, drug test data protection and so on, these policies have broken the policy barriers of new drug research and development, accelerated the speed of new drug research and development, and also spawned a batch of pharmaceutical enterprises with outstanding R & D strength and strong new drug creation ability, such as Kanghong pharmaceutical, Beibei, etc The pharmaceutical industry and so on are favored In the long run, the innovative pharmaceutical industry has a very broad prospect Many top executives of multinational pharmaceutical companies even believe that in the next 5 to 10 years, there will be a number of potential innovative local pharmaceutical companies in China In the capital market, some of the top innovative drug companies in the future will also get a very large growth It is recommended to pay attention to the combination of large-scale pharmaceutical and biotechnology On the one hand, it is suggested to pay attention to the development opportunities of China's large-scale innovative pharmaceutical enterprises represented by Hengrui pharmaceutical, Fosun Pharmaceutical, Lizhu group, etc.; on the other hand, it is suggested to pay attention to the excellent biotechnology companies with characteristic varieties such as guanzhukanghong pharmaceutical and Beida pharmaceutical.